TrialID,Study_design,primary_purpose,manual,study_arm,url,Scientific_title,Conditions,Date_enrollment_format,control_arm,randomisation,blinding,subject_blind,caregiver_blind,investigator_blind,outcome_blind,analyst_blind,prospective,Source_registry,phase_clean,region_Africa,region_N_America,region_L_America,region_Asia,region_Europe,region_Oceania,multicentre,sponsor_type,sample_size,vaccine,conventional,traditional,Bridging_flag,Day_inferred,Date_registration_format,Phase,Public_title,Countries,Primary_sponsor,Interventions
IRCT20200705048011N1,"Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive.",Other,Treatment,covid,http://en.irct.ir/trial/49481,The effect of garlic and cinnamon essential oil on the treatment of patients with  corona (COVID-19),"Covid-19. <br>Coronavirus infection, unspecified;B34.2",2020-08-22,Yes,No,No,No,No,No,No,No,Yes,IRCT,Undefined,No,No,No,Yes,No,No,NA,non_industry,45,NA,NA,NA,FALSE,FALSE,2020-08-16,N/A,Garlic and cinnamon on the treatment of patients with corona,Iran (Islamic Republic of),Sabzevar University of Medical Sciences,"Intervention 1: Intervention group: Recipient of garlic essential oil. Patients in the intervention group will take the drug prepared from garlic for 1 week. A drop of garlic made by Amin Pharmaceutical Company is consumed ten drops daily for a week. Each 10 drops of Garlic contains 250 grams of garlic extract. It should be noted that patients will receive routine medication for coronary artery disease. The trained nurse will perform the intervention. Intervention 2: Control group: No intervantion. Intervention 3: Intervention group: Intervention group: Recipients of cinnamon essential oil. Patients of the second intervention group will take cinnamon medicine for 1 week. Cinnamon drops made by Zardband pharmaceutical company .It will be use three times a day and 5 drops in a glass of water, tea each time. It should be noted that patients will receive routine medication for the treatment of coronary heart disease."
NCT03450915,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).",Treatment,Prevention,im,https://clinicaltrials.gov/show/NCT03450915,"A Pivotal Multi-center, Randomized, Modified Double-blind, Placebo-controlled Phase 3 Trial to Assess the Safety and Clinical Efficacy of M-001 Influenza Vaccine Administered Intra-muscularly Twice in Older Adults and Elderly (=50 Years).",Influenza,2018-08-01,Yes,Yes,Yes,Yes,Yes,Yes,Yes,No,Yes,CT.gov,Phase 3,No,No,No,No,Yes,No,Yes,industry,12463,NA,NA,NA,EUCTR2018-000468-27-HU,FALSE,2018-02-08,Phase 3,A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine,Poland,BiondVax Pharmaceuticals ltd.,Biological: M-001;Biological: Saline
NCT04442048,Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).,Treatment,Prevention,covid,https://clinicaltrials.gov/show/NCT04442048,"COV-IMMUNO: A Randomized, Phase III Trial of Immunization With IMM-101 Versus Observation for the Prevention of Severe Respiratory and COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure",Cancer;Covid-19,2020-06-25,Yes,Yes,No,No,No,No,No,No,Yes,CT.gov,Phase 3,No,Yes,No,No,No,No,NA,NA,1500,NA,NA,NA,FALSE,FALSE,2020-06-19,Phase 3,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,Canada,Canadian Cancer Trials Group,Biological: IMM-101;Other: Observation
